Your browser is no longer supported. Please, upgrade your browser.
Settings
LH [NYSE]
Laboratory Corporation of America Holdings
IndexS&P 500 P/E15.62 EPS (ttm)15.82 Insider Own0.20% Shs Outstand97.40M Perf Week4.56%
Market Cap23.72B Forward P/E15.90 EPS next Y15.55 Insider Trans-2.59% Shs Float96.72M Perf Month7.97%
Income1.56B PEG1.43 EPS next Q7.38 Inst Own94.20% Short Float1.51% Perf Quarter24.34%
Sales13.98B P/S1.70 EPS this Y-7.70% Inst Trans-0.34% Short Ratio2.05 Perf Half Y36.83%
Book/sh84.59 P/B2.92 EPS next Y-27.53% ROA2.00% Target Price269.85 Perf Year31.78%
Cash/sh6.95 P/C35.56 EPS next 5Y10.93% ROE4.80% 52W Range98.02 - 252.45 Perf YTD21.42%
Dividend- P/FCF20.21 EPS past 5Y7.10% ROI7.50% 52W High-3.59% Beta1.04
Dividend %- Quick Ratio1.20 Sales past 5Y14.00% Gross Margin35.40% 52W Low148.29% ATR7.27
Employees65000 Current Ratio1.40 Sales Q/Q33.00% Oper. Margin6.00% RSI (14)63.63 Volatility4.07% 3.26%
OptionableYes Debt/Eq0.71 EPS Q/Q219.40% Profit Margin2.60% Rel Volume1.54 Prev Close247.15
ShortableYes LT Debt/Eq0.67 EarningsFeb 11 BMO Payout0.00% Avg Volume714.30K Price243.38
Recom1.80 SMA204.71% SMA5010.54% SMA20025.13% Volume493,438 Change-1.53%
Jan-11-21Upgrade Argus Hold → Buy $245
Jan-11-21Downgrade Wolfe Research Peer Perform → Underperform
Jan-08-21Downgrade Wolfe Research Outperform → Peer Perform
Jul-14-20Upgrade BofA Securities Neutral → Buy $194 → $220
Jul-13-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Resumed Deutsche Bank Buy $210
May-15-20Upgrade Mizuho Neutral → Buy $158 → $186
Apr-29-20Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-27-20Upgrade Wolfe Research Underperform → Peer Perform
Apr-27-20Upgrade Citigroup Neutral → Buy $204 → $214
Jan-08-20Initiated Wells Fargo Overweight $210
Jul-16-19Upgrade BofA/Merrill Underperform → Neutral
Jun-21-19Upgrade Deutsche Bank Hold → Buy $180 → $220
Apr-02-19Upgrade Jefferies Hold → Buy $154 → $190
Jan-17-19Initiated UBS Buy $169
Jan-03-19Downgrade BofA/Merrill Neutral → Underperform
Dec-03-18Downgrade Craig Hallum Buy → Hold
Oct-30-18Downgrade Argus Buy → Hold
Oct-25-18Downgrade Canaccord Genuity Buy → Hold $190 → $162
Oct-19-18Resumed BofA/Merrill Buy
Feb-23-21 01:26PM  
12:42PM  
12:14PM  
09:15AM  
06:54AM  
Feb-18-21 08:01AM  
Feb-17-21 02:47PM  
09:22AM  
06:57AM  
Feb-16-21 05:44PM  
12:59PM  
Feb-12-21 10:02AM  
Feb-11-21 03:00PM  
02:00PM  
10:35AM  
09:56AM  
08:25AM  
06:58AM  
06:45AM  
Feb-10-21 09:12AM  
08:54AM  
Feb-09-21 11:02AM  
Feb-08-21 10:42AM  
Feb-03-21 04:43PM  
04:30PM  
Feb-01-21 03:39PM  
11:27AM  
Jan-28-21 11:28AM  
01:55AM  
Jan-26-21 08:00AM  
Jan-20-21 12:10PM  
Jan-19-21 08:52AM  
07:00AM  
Jan-15-21 08:00AM  
Jan-13-21 03:18PM  
09:52AM  
Jan-08-21 06:57AM  
Jan-07-21 04:20PM  
01:18PM  
Jan-06-21 07:40AM  
Jan-05-21 10:22AM  
06:59AM  
Jan-04-21 10:07AM  
09:26AM  
Dec-31-20 11:50AM  
09:39AM  
Dec-30-20 10:03AM  
09:57AM  
08:04AM  
08:03AM  
Dec-29-20 10:06AM  
07:36AM  
Dec-27-20 12:10PM  
Dec-24-20 05:50PM  
Dec-23-20 09:44AM  
Dec-22-20 12:45PM  
11:49AM  
Dec-21-20 04:15PM  
08:47AM  
06:57AM  
Dec-18-20 05:50PM  
11:42AM  
11:13AM  
Dec-17-20 03:07PM  
Dec-16-20 02:40PM  
Dec-15-20 01:03PM  
11:50AM  
08:58AM  
Dec-14-20 08:45AM  
Dec-11-20 02:45PM  
Dec-10-20 10:50AM  
10:40AM  
07:42AM  
Dec-09-20 06:47PM  
05:57PM  
09:30AM  
08:44AM  
Dec-08-20 10:31AM  
10:12AM  
Dec-07-20 12:02PM  
11:04AM  
09:38AM  
09:11AM  
Dec-06-20 08:30AM  
Dec-04-20 12:45PM  
09:37AM  
Dec-03-20 09:55AM  
Dec-02-20 02:13PM  
11:40AM  
07:15AM  
Dec-01-20 11:25PM  
Nov-30-20 01:08PM  
Nov-27-20 11:50AM  
11:42AM  
08:50AM  
07:38AM  
Nov-26-20 09:18AM  
Nov-25-20 09:04AM  
06:56AM  
05:39AM  
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular and infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other procedures. In addition, it provides a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, QIAGEN N.V, Ciox Health, Circuit Clinical, and Riverside Medical Group. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 18Option Exercise157.092,166340,2512,660Feb 19 02:17 PM
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 18Sale241.512,317559,589343Feb 19 02:17 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 16Sale236.5520849,2024,426Feb 17 04:28 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 16Sale237.0618844,5674,339Feb 17 04:27 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 05Sale225.8510924,6184,219Feb 08 03:43 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 05Sale225.8520345,8484,152Feb 08 03:40 PM
Williams R SandersDirectorJan 26Option Exercise98.491,300128,0375,246Jan 28 12:11 PM
Schroeder Mark SEVP, President-Diagnostics LabNov 06Sale214.59588126,1793,949Nov 10 10:48 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentNov 04Sale214.141,500321,2047,698Nov 06 09:06 AM
Williams R SandersDirectorJul 08Option Exercise98.491,300128,0376,395Jul 10 04:25 PM
Williams R SandersDirectorJul 08Sale173.121,300225,0565,095Jul 10 04:25 PM
van der Vaart Sandra DEVP, Chief Legal OfficerJul 02Sale170.0043573,9504,044Jul 07 09:38 AM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 24Sale160.33872139,8084,479Jun 26 10:06 AM
KING DAVID PDirectorMay 05Sale160.0031,2505,000,000312,554May 07 12:05 PM
Kirchgraber Paul RCEO, Covance Drug DevelopmentApr 03Option Exercise0.001,01008,459Apr 07 04:21 PM
Seltz Judith CEVP, CHROMar 10Buy168.5633055,625580May 04 10:18 AM
Seltz Judith CEVP, CHROFeb 28Buy174.9425043,735250May 04 10:18 AM